drugset
drugset / Trial / NCT05201911

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

NCT05201911 ↗

Phase 1 Completed 13 enrolled Attralus, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.

Timeline

Start
2021-11-30
Primary completion
2022-09-06
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AT03 Protein / enzyme biologic — Intravenous

Indications

amyloidosis